PP_1170x120_10-25-21

Adamis Pharmaceuticals

US WorldMeds, Adamis Pharmaceuticals announce U.S. launch of ZIMHI Naloxone Product

US WorldMeds, Adamis Pharmaceuticals announce U.S. launch of ZIMHI Naloxone Product

LOUISVILLE, Ky. — USWM (US WorldMeds), and Adamis Pharmaceuticals Corporation,  today announced the U.S. launch and availability of ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present. According to the Centers

Adheris Health